An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma.

Trial Profile

An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Haemangiosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 26 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 09 Apr 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top